Patient-Derived Xenograft/PDX Model Market by Type (Mice, Rat), Implantation Method (Subcutaneous, Orthotopic), Tumor Type (Respiratory, Hematological), Application (Drug Development, Biobanks), End User (Pharma, Biotech, CROs) - Global Forecast to 2028

Continuous Support for Cancer Research From the Public & Private Sectors is to Drive the Market

The patient-derived xenografts/ PDX model market is projected to reach USD 687 million by 2028 from USD 366 million in 2023, at a CAGR of 13.4% during the forecast period. The key factors driving the growth of the global patient-derived xenograft/ PDX model market are the enhanced preclinical predictability, advancement of personalized medicine, and rise in the prevalence of cancer. However, ethical concerns surrounding the use of animal models are expected to restrain market growth to a certain extent.

The patient-derived xenografts/ PDX models market has been segmented based on type, implantation method, tumor type, application, end-user, and region. 

By type, the mouse model segment accounted for the largest share of the patient-derived xenografts/ PDX models market.

Based on type, the patient-derived xenografts/ PDX models market is categorized into mouse model and rat model. The mouse model segment is the largest and fastest-growing segment in the market in 2023, owing to ease of manipulation and procurement, and the minimum requirement for keeping them under observation compared to rats in the facilities has led to a higher growth rate for products in the patient-derived xenografts/ PDX models market.

By implantation method, subcutaneous implantation segment accounted for the largest share in the patient-derived xenografts/ PDX models market.

Based on implantation method, the market is segmented into subcutaneous implantation, orthotopic implantation, and other implantation methods (heterotopic implantation, intraocular implantation, and under the renal capsule). In 2023, the subcutaneous segment accounted for the largest share and the fastest-growing segment of the patient-derived xenografts/ PDX models market. Subcutaneous implantation involves implanting patient-derived tumor tissue under the skin of a host animal (often a mouse). This method is relatively simple and minimally invasive compared to other implantation methods, making it a practical choice for researchers.

North America: the largest share of the patient-derived xenografts/ PDX models market.

North America accounted for the largest share of the patient-derived xenografts/ PDX models market. The region possesses a highly developed and robust biopharmaceutical industry, with advanced research and clinical infrastructure. This environment facilitates efficient collaboration between academia, research institutions, and pharmaceutical companies, enabling the effective utilization and adoption of PDX models.

Secondly, North America's regulatory framework supports the integration of innovative technologies, including PDX models, in preclinical and clinical research. The stringent regulatory standards ensure that PDX models are validated and applicable for drug development processes, thereby bolstering investor and industry confidence.

Moreover, the APAC region offers lucrative growth potential for the PDX models market. This region benefits from a robust healthcare infrastructure, a burgeoning biopharmaceutical industry, and a large patient population, fostering an ideal setting for PDX model utilization.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 63% and Demand Side- 37%
• By Designation: Executives - 45%, Research Scientists- 30%, and Managers - 25%
• By Country: North America- 40%, Europe- 25%, Asia Pacific- 20%, Latin America - 10%, and Middle East Africa- 5%

Prominent Players

• JSR Corporation (Japan)
• Wuxi Apptec (China)
• The Jackson Laboratory (US)
• Charles River Laboratories International, Inc. (US)
• Taconic Biosciences, Inc. (US)
• Oncodesign Precision Medicine (France)
• Inotiv, Inc. (US)
• Pharmatest Services (Finland)
• Hera BioLabs (US)
• EPO Berlin-Buch GmbH (Germany)
• Xentech (France)
• Urosphere (France)
• Altogen Labs (US)
• Abnova Corporation (US)
• Genesis Biotechnology Group (US)
• Biocytogen Pharmaceuticals Co., Ltd. (China)
• Creative Animodel (US)
• BioDuro-Sundia (US)
• Aragen Life Sciences (India)
• Shanghai LIDE Biotech Co., Ltd. (China)
• Certis Oncology Solutions (US)
• InnoSer (Netherlands)
• IVRS AB (Sweden)
• Beijing IDMO Co. Ltd. (China)
• Shanghai Chempartner Co. Ltd. (China)

Research Coverage:

This report provides a detailed picture of the patient-derived xenografts/ PDX models market. It aims to estimate the size and future growth potential of the market across different segments, such as type, implantation method, tumor type, application, and end-user, and region (North America, Europe, Asia Pacific, Latin America, and Middle East Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall patient-derived xenografts/ PDX models market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (growing demand for personalized medicine, technological advancements in PDX technology, and rising investments for cancer research), restraints (FDA’s announcement to discontinue animal models for clinical trials), opportunities (emergence of CRISPR in biomedical research), and challenges (development of alternative animal testing methods) influencing the growth of the patient-derived xenografts/PDX models market.
• Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the patient-derived xenografts/ PDX models market. 
• Market Development: Comprehensive information about lucrative markets- the report analyses the patient-derived xenografts/ PDX models market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the patient-derived xenografts/ PDX models market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like JSR Corporation (Japan), The Jackson Laboratory (US), and Charles River Laboratories International, Inc. (US), among others, in the patient-derived xenografts/ PDX models market strategies. The report also helps stakeholders understand the pulse of the patient-derived xenografts/ PDX models market and provides them with information on key market drivers, restraints, challenges, and opportunities.